Illinois Lawmakers Debate Prescription Drug Affordability Board

Illinois legislators are close to concluding their spring session. They are focusing on a key bill to establish a Prescription Drug Affordability Board. This initiative aims to address the high costs of medication in the state, reflecting a broader national issue. Proponents argue that this board could help manage soaring drug prices.

The House Executive Committee passed the bill, with an 8-4 vote, moving it to the full House for consideration. The aim is to have a state-level panel review medication costs and cap prices deemed excessive. However, critics worry about adding bureaucracy without effective price controls.

State Rep. Nabeela Syed, D-Palatine, spearheads this initiative. During a committee hearing, she described the bill as “heavily negotiated.” The proposal had faced earlier delays but is now moving forward.

The board would consist of five members appointed by the governor. Their duty would be to evaluate drugs and set price limits, allowing pharmaceutical companies to defend their pricing before final decisions. Additionally, the board hopes to improve drug access in underprivileged areas.

This initiative ties state drug prices to recent Medicare negotiations made possible by the 2022 Inflation Reduction Act. For example, Medicare’s negotiation led to significant price reductions, like Januvia’s cost decreasing from $527 to $113 per month. Under the bill, Illinois would adopt these Medicare rates for all healthcare plans, though Medicaid and state employee plans need separate agreement.

Anusha Thotakura from Citizen Action/Illinois highlights a report showing Illinois overspending by over $190 million due to not using Medicare’s negotiated rates. Despite disagreements over figures, the report underscores serious budgeting issues. As Illinois faces financial constraints, the bill looks to avoid unnecessary expenditures.

Board membership requires healthcare expertise, prohibiting ties to drug manufacturers. Members serve staggered five-year terms supported by a 15-member council with multiple appointments. Decisions can be appealed and reviewed. The Illinois attorney general’s office might enforce the legislation, subject to legislative audit and review.

Prescription drug affordability boards exist in about a dozen other states. Although similar boards have not shown significant savings, states like Colorado, Minnesota, and Maryland allow these entities to set upper payment limits on drugs.

The Pharmaceutical Research and Manufacturers of America (PhRMA) opposes the bill. They argue that state-level adaptations of Medicare pricing are not suitable for local markets. Deputy Minority Leader Ryan Spain also voices concerns about lacking oversight, questioning the absence of a state agency to manage the board.

Rep. Syed countered that the board functions independently and has limited budget needs. Meanwhile, Gov. JB Pritzker’s office remains undecided, although the Senate passed another consumer protection bill banning misleading service fees.